Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 5/20 | 0.43 |
| ▸ | NMT2 | O60551 | 4/20 | 0.43 |
| ▸ | NPY4R | P50391 | 7/20 | 0.42 |
| ▸ | NPY1R | P25929 | 4/20 | 0.42 |
| ▸ | NPY2R | P49146 | 4/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13655538 | 0.99 | NMT1 (0.45) | NMT1NMT2NPY4RNPY1RNPY2R | |
| SCHEMBL31696330 | 0.96 | NMT1 (0.46) | NMT1NMT2NPY4RNPY1RNPY2R | |
| SCHEMBL30193233 | 0.94 | NMT1 (0.44) | NMT1NMT2NPY4RNPY1RNPY2R | |
| SCHEMBL29678519 | 0.93 | NMT1 (0.46) | NMT1NMT2NPY4RNPY1RNPY2R | |
| SCHEMBL30395232 | 0.93 | NPY4R (0.45) | NMT1NMT2NPY4RNPY1RNPY2R | |
| SCHEMBL31410685 | 0.93 | NPY4R (0.43) | NMT1NMT2NPY4RNPY1RNPY2R | |
| SCHEMBL29721007 | 0.93 | NMT1 (0.43) | NMT1NMT2NPY4RNPY1RNPY2R | |
| SCHEMBL29678655 | 0.91 | NMT1 (0.43) | NMT1NMT2NPY4RNPY1RNPY2R | |
| SCHEMBL29489381 | 0.91 | OPRL1 (0.44) | NMT1NMT2NPY4RNPY1RNPY2R | |
| SCHEMBL29642947 | 0.90 | TFPI (0.44) | NMT1NMT2NPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247732-A1 | Synthesis of glycopeptides with superior pharmacokinetic properties | OPTIMER PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247732-A1 | Synthesis of glycopeptides with superior pharmacokinetic properties | OPTIMER PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247732-A1 | Synthesis of glycopeptides with superior pharmacokinetic properties | VIP, MGAT3, UGGT1 | NMT1 49/4885NMT2 69/4885NPY4R 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.